April 19, 2012Open Access
Clopidogrel: A Case for Indication-Specific Pharmacogenetics
Key Result
CYP2C19*2 genotype impacts protection from major adverse cardiovascular outcomes during clopidogrel therapy following percutaneous coronary intervention, but not for other indications.
PICO
Population
Cardiovascular disease requiring clopidogrel therapy
Intervention / Comparator
Clopidogrel
Primary Outcome
Major adverse cardiovascular outcomes
Abstract
The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Cite this study
Johnson et al. (Thu,) conducted a review in Cardiovascular disease requiring clopidogrel therapy. Clopidogrel was evaluated on Major adverse cardiovascular outcomes. CYP2C19*2 genotype impacts protection from major adverse cardiovascular outcomes during clopidogrel therapy following percutaneous coronary intervention, but not for other indications.
synapsesocial.com/papers/6a088272ad370a6b44de252f — DOI: https://doi.org/10.1038/clpt.2012.21
Authors
J
Julie A. Johnson
Broad Institute
Dan M. Roden
General Cardiology
L
Lawrence J. Lesko
American Association of Colleges of Pharmacy
Journals
Clinical Pharmacology & Therapeutics
Actions
Institutions
Stanford University
University of Maryland, College Park
University of Florida
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...